Worldwide treatment of hepatitis C could be within sight at the right cost

February 23, 2015
Worldwide treatment of hepatitis C could be within sight at the right cost
A 12-week course of the new drug sofosbuvir in the US is priced at as much as $84,000 per person

Lowering the cost of hepatitis C drugs is possible and key to achieving global access to treatment, according to new research by the University of Liverpool and Imperial College London.

There are an estimated 185 million people infected with the hepatitis C virus worldwide and 160,000 in Britain. Currently there is no vaccine and, if left untreated, infection can lead to cirrhosis and liver cancer, causing up to 500,000 related deaths globally per year.

Hepatitis C is particularly problematic in low to ; for example 12 million people are infected in Egypt.

A new and effective generation of direct-acting (DAAs) has been developed to treat hepatitis C. However, at present these drugs are highly expensive. A 12-week course of the new drug sofosbuvir in the US is priced at as much as $84,000 per person and £55,440 in the UK. The NHS has recently delayed introduction of sofosbuvir due to its high price.

The treatment of HIV provides a precedent for cutting the costs of drugs on a large scale to make them available across the world. The drugs that have been rolled out worldwide for HIV are similar in chemical structure and mechanisms to the new generation of hepatitis C drugs.

Monitoring costs

Researchers at Liverpool believe that it is feasible that global hepatitis C treatment could be achieved if the manufacturing and monitoring of costs of those drugs were minimised in the same way as with HIV treatments, which involved the lifting of patents to allow drugs to be made by generic manufacturers.

In the study, published in Hepatology, the researchers used HIV drugs as a framework for the analysis to explore what would be possible if drugs were produced at a large scale with the removal of patents to enable generic versions of these DAAs to be manufactured. This is feasible since India has recently filed a patent opposition to sofosbuvir and, if successful, this would mean the patent would no longer restrict the manufacture of the and could be made by a range of manufacturers.

By taking a bottom-up approach using information on the drugs' raw materials, molecular structure and doses, the researchers estimated that if production was done at a large enough scale, it may be possible to dramatically reduce the cost of these news drugs. The study estimated that to treat at least five million people with a combination of the two DAAs sofosbuvir and daclatasvir could cost $122 per person.

Bringing down the price

Co-author, Dr Andrew Hill, from the University of Liverpool's Institute of Translational Medicine, said: "As hepatitis C drugs are so similar to those used to treat HIV we assumed they have the potential to be made in the same way; producing the drugs at economies of scale in large factories and within a freely competitive market where patents have been lifted to allow generic production.

"We know from the experience of HIV treatment that charitable funders want to be able to donate a large sum of money and know it will treat a large amount of people. Our results indicate that this is possible by bringing down the price of hepatitis C drugs for a set target for the number treated."

Through a review of clinical trials, the study identified the four most effective combination regimes of DAAs for a 12-week treatment course for Hepatitis C. The study estimated the minimum costs of treatment by this new generation of DAAs, assuming large scale manufacture to treat at least five million patients per year, in a freely competitive market without the limitations of current patents. The analysis involved going back to the basic chemistry of the drugs to ascertain the cost of the raw materials, synthesis and manufacture of the drugs.


Dr Graham Cooke, from the Department of Medicine at Imperial College London, said: "We now have treatments to deal with C, but there are operational, legal and political barriers preventing us from ensuring access for people on a global and national scale.

"To break down these barriers, we need to learn lessons from the large-scale rollout of HIV treatment and accelerate the process. In this study we have estimated the possible reduction in cost of these new drugs if some of these barriers are removed and they can be produced at a large scale with free competition and improved production efficiency. "

The results showed that the combination of sofosbuvir and daclatasvir to treat five million people could potentially cost $122 per person. These two drugs are already licensed and considered to be the most promising for large-scale programmes.

Explore further: WHO urges global push to treat hepatitis C (Update)

More information: van de Ven, N., Fortunak, J., Simmons, B., Ford, N., Cooke, G. S., Khoo, S. and Hill, A. (2015), "Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus." Hepatology. doi: 10.1002/hep.27641

Related Stories

WHO urges global push to treat hepatitis C (Update)

April 9, 2014
The World Health Organization called Wednesday for a dramatic increase in screening and treatment of hepatitis C, saying higher demand would help drive down the cost of drugs for the disease.

French charity attacks Gilead patent for hepatitis drug

February 10, 2015
French charity Medecins du Monde (MdM) on Tuesday said it was contesting a European patent awarded to a hepatitis drug made by US firm Gilead Sciences, arguing the treatment was too costly.

Spain vows hepatitis C action after calls for new drugs

January 12, 2015
Spain's government Monday promised new measures to fight hepatitis C, following protests by patients who complained authorities were denying them the latest drugs to treat the deadly liver disease.

EASL publishes online recommendations on the management of hepatitis C

April 9, 2014
The European Association for the Study of the Liver (EASL) will this week be announcing new on-line recommendations on the management of hepatitis C (HCV) at the International Liver Congress (ILC). These EASL recommendations ...

Aetna picks Gilead Sciences hepatitis C drugs over AbbVie's

January 16, 2015
Insurer Aetna has made new hepatitis C drugs from Gilead Sciences Inc. preferred treatments for customers with the liver-destroying virus.

High hepatitis C cure rate seen in NIH-led trial of six-week oral drug regimens

January 12, 2015
Thirty-eight of 40 volunteers with hepatitis C virus (HCV) infections who received a combination of three direct-acting oral drugs for six weeks were cured in a clinical trial conducted at the National Institutes of Health ...

Recommended for you

Alcohol consumption and metabolic factors act together to increase the risk of severe liver disease

November 22, 2017
A new study provides insights into the interaction between alcohol consumption and metabolic factors in predicting severe liver disease in the general population. The findings, which are published in Hepatology, indicate ...

Gastric acid suppressant lansoprazole may target tuberculosis

November 21, 2017
A cheap and widely used drug, used to treat conditions such as heartburn, gastritis and ulcers, could work against the bacteria that cause tuberculosis (TB), according to new research from UCL and the London School of Hygiene ...

Improving prediction accuracy of Crohn's disease based on repeated fecal sampling

November 21, 2017
Researchers at the University of California San Diego Center for Microbiome Innovation (CMI) have found that sampling the gut microbiome over time can provide insights that are not available with a single time point. The ...

Anti-malaria drug shows promise as Zika virus treatment

November 17, 2017
A new collaborative study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) and UC San Diego School of Medicine has found that a medication used to prevent and treat malaria may also be effective ...

Decrease in sunshine, increase in Rickets

November 17, 2017
A University of Toronto student and professor have teamed up to discover that Britain's increasing cloudiness during the summer could be an important reason for the mysterious increase in Rickets among British children over ...

Scientists identify biomarkers that indicate likelihood of survival in infected patients

November 17, 2017
Scientists have identified a set of biomarkers that indicate which patients infected with the Ebola virus are most at risk of dying from the disease.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.